Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome) is Buildings and Property in Japan that focus on reduced fat mass business. They cover business area such as an investigational therapy, Prader-Willi syndrome, PWS, body weight gain, reduce fat mass, mouse, favourable pharmacokinetic, safety, profile.
-
Reduced Fat Mass
-
Tokyo
Japan
Private
an investigational therapyPrader-Willi syndromePWSbody weight gainreduce fat massmousefavourable pharmacokineticsafetyprofile
* We use standard office opening hours in near Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Takeda Pharmaceutical Company (Rights Of RM-853 Therapy For Prader-Willi Syndrome) is Buildings and Property business from Japan that founded in - ( years old in ), Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome) business is focusing on Reduced Fat Mass.
Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome) headquarter office and corporate office address is located in Tokyo Japan.
Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome) was founded in Japan.
In , Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome) is currently focus on reduced fat mass sector.
Above is snippet of Google Trends for "reduced fat mass" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
